is oral or injectable semaglutide better for weight loss Best GLP-1 Loss: vs Semaglutide, Side Effects, and Long-Term Tolerance Oral GLP-1 Medication Helps Patients
Description
For these reasons, we always recommend staying in contact with your healthcare provider any time you undertake a diet or other weight loss strategy

If you are worried, you should speak to your doctor for advice
:max_bytes(150000):strip_icc()/Health-GLP1-pill-vs-shot-137cf589ddca421bb0aef5c5d7aec64a.png)
The Rise to Prominence Despite being discovered in the 1970s, GLP-1 drugs have only recently gained widespread attention

You should not take Contrave if you: Have uncontrolled high blood pressure Have anorexia or bulimia Have or have had seizures Use other medicines that contain bupropion such as Wellbutrin, Wellbutrin SR, Wellbutrin XL, Aplenzin, or Zyban Are undergoing an abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs Drink a lot of alcohol and abruptly stop drinking Have kidney disease Have liver disease (it may cause liver dysfunction or hepatitis) Are depressed or have suicidal feelings Have current or recent (within the past 7-14 days) use of opioids or opiate drugs You should not take Contrave under these circumstances either: If youre pregnant, breastfeeding, or planning to become pregnant If youve taken an MAOI (monoamine oxidase inhibitor), such as Nardil, Parnate, or Marplan in the past 14 days If youre taking any opioids or opiate drugs If youre dependent on opioids or using methadone or buprenorphine If you are in opioid withdrawal If you take opioids or opiates right after stopping Contrave, you may be more sensitive to them and require lower doseswhich poses a risk of overdose

NICE has approved semaglutide 2.4 mg (Wegovy) for use within specialist weight management services (NICE TA875), subject to specific eligibility criteria including a BMI of 35 kg/m or above (or 32.5 kg/m or above in people from certain ethnic minority backgrounds at higher metabolic risk) alongside at least one weight-related comorbidity

Kikkawa, K